1. Home
  2. List
Reference Patent

Reference - List

When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
  • 14 Hits
  • Search Condition : Filter (MeSH = Bone Density / drug effects)
Species Resource Title
Human and Animal Cells MC3T3-E1(RCB1126) Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts.
Human and Animal Cells MC3T3-E1(RCB1126) Anti-Osteoporotic Effect of Morroniside on Osteoblast and Osteoclast Differentiation In Vitro and Ovariectomized Mice In Vivo.
Human and Animal Cells MC3T3-E1(RCB1126) Scopolin Attenuates Osteoporotic Bone Loss in Ovariectomized Mice.
Human and Animal Cells ST2(RCB0224) FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
Human and Animal Cells MC3T3-E1(RCB1126) Locally delivered ethyl-2,5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model.
Human and Animal Cells MC3T3-E1(RCB1126) Oxygen ultra-fine bubbles water administration prevents bone loss of glucocorticoid-induced osteoporosis in mice by suppressing osteoclast differentiation.
Human and Animal Cells RAW 264(RCB0535) DGKζ Downregulation Enhances Osteoclast Differentiation and Bone Resorption Activity Under Inflammatory Conditions.
Human and Animal Cells MC3T3-E1(RCB1126) The effect of Lycii Radicis Cortex extract on bone formation in vitro and in vivo.
Human and Animal Cells RAW 264(RCB0535) Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.
Human and Animal Cells MC3T3-E1(RCB1126) , ST2(RCB0224) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Human and Animal Cells MC3T3-E1(RCB1126) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Human and Animal Cells ATDC5(RCB0565) Chondrocyte p21(WAF1/CIP1) expression is increased by dexamethasone but does not contribute to dexamethasone-induced growth retardation in vivo.
Human and Animal Cells C2C12(RCB0987) RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro.
Human and Animal Cells MC3T3-E1(RCB1126) Reduction of protein phosphatase 2A Cα enhances bone formation and osteoblast differentiation through the expression of bone-specific transcription factor Osterix.